?
1.Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel (CEO, COO, CMO, CSO, etc.), financial officer, accounting officer, corporate governance officer, chief information security officer, research and development officer, internal audit officer, or designated and non-designated representatives):Internal audit officer 2.Date of occurrence of the
1.Date of the board of directors' resolution：2026/03/12 2.Shareholders meeting date：2026/06/17 3.Shareholders meeting location：2F., No. 12, Zhouzi St., Neihu Dist., Taipei City, Taiwan 4.Shareholders' meeting will be held by means of (physical shareholders' meeting/ hybrid shareholders' meeting / virtual-only shareholders' meeting)：physical shareholders' meeting 5.Cause for convening the meeting (1)：Report item(s) (1)：2025
1.Date of the board of directors resolution:2026/03/12 2.Year or quarter which dividends belong to :2025 (Year) 3.Period which dividends belong to:2025/01/01 to 2025/12/31 4.Appropriations of earnings in cash dividends to shareholders (NT$ per share):2 5.Cash dividends distributed from legal reserve and capital reserve to shareholders (NT$ per share):0 6.Total amount
1.Date of a notice of the board of directors meeting is issued:2026/03/04 2.Expected date of the board of directors meeting is convened:2026/03/12 3.Expected year and quarter of the financial reports or the annual self-assessed financial information submitted to the board of directors or approved by the board
1.Date of occurrence of the event:2025/12/30 2.Company name:Handa Pharmaceuticals, Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office 4.Reciprocal shareholding ratios:NA 5.Cause of occurrence:Pursuant to the ”Taiwan Securities Association Rules for Underwriters Handling Initial Listing/OTC Cases,” the Company announces the result of the price stabilization operation